Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Tue 06:31
BRIEF-SynAct Pharma Q3 Net Income SEK -32.177 Million Nov 03 (Reuters) - SynAct Pharma Q3 adjusted EPS SEK -0.57.
- Q3 operating expenses SEK 30.087 million
- Q3 cash flow from operating activities SEK -18.714 million
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development